Parkinson's disease and growth factors - are they the answer?

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 3, 2009, Pages

  Barker, Roger A ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

GDNF; Neurotrophic factors; Neurturin; Parkinson's disease; Trials

Indexed keywords

CERE 120; DOPAMINE; FLUORODEOXYGLUCOSE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; LEVODOPA; LIATERMIN; NEUROTROPHIC FACTOR; NEURTURIN; PLACEBO; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; AUTOPSY; CELL SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; HUMAN; LHERMITTE DUCLOS DISEASE; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; FLUORODEOXYGLUCOSE F18; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MULTICENTER STUDIES AS TOPIC; NEURONS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 72149103835     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70810-7     Document Type: Article

References (35)

1. Colangelo A.M., Finotti N., Ceriani M., Alberghina L., Martegani E., Aloe L., et al. Recombinant human nerve growth factor with a marked activity in vitro and in vivo. Proc Natl Acad Sci USA 102 (2005) 18658-18663
2. Yuen E.C., and Mobly W.C. Therapeutic potential of neurotrophic factors for neurological disorders. Ann Neurol 40 (1996) 346-354
3. Siegel G.J., and Chauhan N.B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Rev 33 (2000) 199-227
4. Ebadi M., Bahir R.M., Heidrick F.M., et al. Neurotrophins and their receptors in nerve injury and repair. Neurochem. Int 30 (1997) 465-474
5. Schapira A.H. Treatment options in the modern management of Parkinson's Disease. Arch Neurol 64 (2007) 1083-1088
6. Wijeyekoon R., and Barker R.A. Cell replacement therapy in Parkinson's disease. Biochim Biophys Acta 1792 (2009) 688-702
7. Evans J.R., and Barker R.A. Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets 12 (2008) 437-447
8. Lin L.-F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
9. Kirik D., Georgievska B., Rosenblad C., and Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur J Neurosci 13 (2001) 1589-1599
10. Aoi M., Date I., Tomita S., and Ohmoto T. Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system. Neurol Res 22 (2000) 832-836
11. Aoi M., Date I., Tomita S., and Ohmoto T. GDNF induces recovery of the nigrostriatal system in the rat brain following intracerebroventricular or intraparenchymal administration. Acta Neurochir 142 (2000) 805-810
12. Yasuhara T., Shingo T., Muraoka K., et al. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson's disease. J Neurosurg 102 (2005) 80-89
13. Emerich D.F., Winn S.R., Christenson L., Palmatier M.A., Gentile F.T., and Sanberg P.R. A novel approach to neural transplantation in Parkinson's disease: use of polymer-encapsulated cell therapy. Neurosci Biobehav Rev 16 (1992) 437-447
14. Kordower J.H. In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann Neurol 53 suppl 3 (2003) S120-S134
15. Kordower J.H., Emberg M.E., Bloch J., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
16. Chtarto A., Yanq X., Bockstael O., et al. Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. Exp Neurol 204 (2007) 387-399
17. Nutt J.G., Burchel K.J., Comella C.L., et al. Randomised, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60 (2002) 69-73
18. Gill S.S., Patel N.K., Hotton G.R., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nat Med 9 (2003) 589-594
19. Patel N.K., Bunnage M., Plaha P., Svensden C.N., Heywood P., and Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two year outcome study. Ann Neurol 57 (2005) 298-302
20. Love S., Plaha P., Patel N.K., Hotton G.R., Brooks D.J., and Gill S.G. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nature Med 11 (2005) 703-704
21. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., and Young B. Improvement of bilateral motor functions in patients with Parkinson's disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102 (2005) 216-222
22. Slevin J.T., Gash D.M., Smith C.D., et al. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson's disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 106 (2007) 614-620
23. Lindvall O., Widner H., Rehncrona S., et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 31 (1992) 155-165
24. Lindvall O., Sawle G., Widner H., et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 35 (1994) 172-180
25. Lang A.E., Gill S.S., Patel N.K., et al. Randomised controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson's disease. Ann Neurol 59 (2006) 459-466
26. Hutchinson M., Gurney S., and Newson R. GDNF in Parkinson's disease: an object lesson in the tyranny of type II. J Neurosci Methods 163 (2007) 190-192
27. Matcham J., McDermott M.P., and Lang A.E. GDNF in Parkinson's disease: the perils of post-hoc power. J Neurosci Methods 163 (2007) 193-196
28. Barker R.A. Continuing trials of GDNF in Parkinson's disease. Lancet Neurology 5 (2006) 285-286
29. Sherer T.B., Fiske B.K., Svendsen C.N., Lang A.E., and Langston J.W. Crossroads in GDNF therapy for Parkinson's disease. Mov Disord 21 (2006) 136-141
30. Lang A.E., Langston W.J., Stoessl A.J., et al. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurology 5 (2006) 200-202
31. Penn R.D., Dalvi A., Slevin J., et al. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurology 5 (2006) 202-203
32. Peck P. Amgen decision to halt GDNF clinical trials and withdraw the drug triggers protest from researchers and patients. Neurol Today: Am Acad Neurol 5 (2005) 4
33. th annual meeting, 2006. San Diego, CA.
34. http://www.ceregene.com
35. Lang A.E., and Obeso J.A. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurology 3 (2004) 309-316